

Non-clinical study of IBD using Live Microbial Gene Therapy based on recombinant microbial Toolbox



IMMUNOLOGY	Preclinical
Product Type	Engineered Live Biotherapeutic Products
Indication	Inflammatory Bowel Diseases
Target	Inflammation-induced innate immunity
MoA(Mechanism of Action)	Regulation of intestinal inflammation by IL-17-mediated innate immune control through VIP (Vasoactive Intestinal Peptide)-secreting engineered Live Biotherapeutic Products (LIV001)
Competitiveness	<ul style="list-style-type: none"> LIV001 is a next-generation Live Microbial Gene Therapy based on the engineering platform eLBP[®] designed to express IBD therapeutics. eLBP[®] is a vector- and marker-free genetic engineering platform. As a universal platform applicable to bacterial genus, it boasts superior therapeutic productivity compared to existing platforms. Unlike systemic treatment of immunosuppressors or biologics, orally administered LIV001 are not exposed to blood system and expected not to trigger side effects.
Development Stage	Preclinical
Route of Administration	Oral